Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Vor Biopharma stock

Own Vor Biopharma stock in just a few minutes.

Vor Biopharma Inc complete an upsized $176.9 million IPO, offering 9.83 million shares at $18 each.

The stock opened at $42.02 was jumped 104.9% in early action.

How to buy shares in Vor Biopharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VOR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Vor Biopharma share price

Use our graph to track the performance of VOR stocks over time.

Vor Biopharma shares at a glance

Information last updated 2021-04-21.
52-week range$18.00 - $59.00
50-day moving average $36.85
200-day moving average $39.90
Wall St. target price$48.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Vor Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Vor Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vor Biopharma financials

Gross profit TTM $0
Return on assets TTM -63.23%
Return on equity TTM -155.02%
Profit margin 0%
Book value N/A
Market capitalisation $1 billion

TTM: trailing 12 months

Shorting Vor Biopharma shares

There are currently 1.5 million Vor Biopharma shares held short by investors – that's known as Vor Biopharma's "short interest". This figure is 50.3% up from 971,094 last month.

There are a few different ways that this level of interest in shorting Vor Biopharma shares can be evaluated.

Vor Biopharma's "short interest ratio" (SIR)

Vor Biopharma's "short interest ratio" (SIR) is the quantity of Vor Biopharma shares currently shorted divided by the average quantity of Vor Biopharma shares traded daily (recently around 328826.57657658). Vor Biopharma's SIR currently stands at 4.44. In other words for every 100,000 Vor Biopharma shares traded daily on the market, roughly 4440 shares are currently held short.

To gain some more context, you can compare Vor Biopharma's short interest ratio against those of similar companies.

However Vor Biopharma's short interest can also be evaluated against the total number of Vor Biopharma shares, or, against the total number of tradable Vor Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vor Biopharma's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Vor Biopharma shares in existence, roughly 40 shares are currently held short) or 0.0982% of the tradable shares (for every 100,000 tradable Vor Biopharma shares, roughly 98 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vor Biopharma.

Find out more about how you can short Vor Biopharma stock.

Vor Biopharma share dividends

We're not expecting Vor Biopharma to pay a dividend over the next 12 months.

Vor Biopharma overview

Vor Biopharma, Inc. , early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site